HELE

The FY2026 headline is alarming — a -$899M net loss (-$39.08 diluted EPS) and negative -43.8% operating margin — but the numbers and the MD&A together say this is a paper loss, not a cash loss. Management's MD&A explicitly attributes the GAAP result to asset impairment charges, a discrete Barbados tax-reform charge, valuation allowances on deferred tax assets, CEO-succession costs, and restructuring — all largely non-cash or one-time. The tell is in the cash statement: operating cash flow actually rose 51% to $171M, and after $39.2M capex the business threw off ~$132M of free cash flow. Against a $654M market cap that is a ~20% FCF yield, and the stock trades at just 0.4x sales with a still-healthy 45.7% gross margin and a genuine brand portfolio (OXO, Hydro Flask, Osprey, Vicks, Braun, Honeywell). On the surface this looks like a deeply mispriced value name.

The reason I stop short of buy is that the operating deterioration underneath the impairment is real and not yet arrested. Revenue has fallen four straight years — $2.22B → $2.07B → $2.01B → $1.91B → $1.79B — with the FY2026 -6.4% drop the steepest of the run, so the impairment is the accounting system catching up to a genuinely shrinking business, not a random write-down. The balance sheet leaves little margin for error: only $18.9M of cash against $781M of total debt ($756M long-term + $25M current, the latter up 167%), and the $899M loss cut equity 53% and retained earnings 69%. Liabilities-to-equity sits at 1.65x. This is a levered company leaning entirely on its cash generation to service debt while it tries to stabilize.